NX PharmaGen

(No Reviews)
4350 Brownsboro Rd, Louisville, KY 40207, USA

(502) 893-4570


Contact and Address

Category: Health,
Address: 4350 Brownsboro Rd, Louisville, KY 40207, USA
Postal code: 40207
Phone: (502) 893-4570
Website: http://www.nxpharmagen.com/contact-us

Location & routing

Get Directions

Most Recent Reviews

There are no reviews yet!
You can review this Business and help others by leaving a comment. If you want to share your thoughts about NX PharmaGen, use the form below and your opinion, advice or comment will appear in this space.

Write a Review


NX PharmaGen On the Web

Nx Pharmagen

NX PharmaGen's groundbreaking technologies are paving the way for patients to realize the promise of personalized medicine in cancer, prenatal care, and other conditions. The next generation of medical care is dawning, and the tools that NX PharmaGen is developing may play a key role in solving the...


NX Pharmagen Inc. - Who is raising money? | SEC filings of...

NX Pharmagen Inc. Industry: Other Health Care CIK Number: 0001508691 IRS Number: 272135794 Address: 4350 BROWNSBORO ROAD SUITE 110 LOUISVILLE 40207 Phone number: 502-893-4570. Directors and Executives of NX Pharmagen Inc.


NX PharmaGen Company Profile: Valuation & Investors | PitchBook

NX PharmaGen General Information. Description. Developer of molecular diagnostics and tumor imaging platform intended to diagnose preterm birth, cancer, and other diseases. Louisville, KY 40207. United States. +1 (502) 000-0000.    Want detailed data on 2M+ companies?


NX PharmaGen (@NXPharmaGen) | Твиттер

Последние твиты от NX PharmaGen (@NXPharmaGen). We are developing blood-based diagnostic tests which exploit biomarkers found within circulating exosomes, for prenatal and cancer applications. NX PharmaGen начал(а) читать.


NX Pharmagen - Crunchbase Company Profile & Funding

NX PharmaGen's business model is to acquire, develop, and monetize mature clinical-stage breakthrough technologies. The company's lead program is a disruptive diagnostic technology, termed the NeXosomeTM Platform, which is designed to yield


NX PharmaGen | VisionTech

NX PharmaGen has developed a novel molecular diagnostics platform for preterm birth, cancer and other diseases. The NeXosome™ Platform enables the collection of valuable diagnostic data via the analysis of biomarker-containing microvesicles (a.k.a. exosomes) shed from placental, tumor, or...


NX Pharmagen Technologies — English version — IVAO

Venture companies. NX Pharmagen Technologies. NX Pharmagen Technologies. Send request.


NX PharmaGen - CB Insights

NX PharmaGen acquires, develops, and monetizes mature clinical-stage technologies. The company's lead program is a disruptive diagnostic technology, termed the NeXosome Platform. Through its wholly-owned subsidiary, NX Development Corp., the company has obtained options to pursue additional...


NX PharmaGen Canada Inc. :: New Brunswick... :: OpenCorporates

Free and open company data on New Brunswick (Canada) company NX PharmaGen Canada Inc. (company number 664576). NX PharmaGen Canada Inc. Company Number. 664576.


NX Pharmagen Competitors, Revenue and... - Owler Company Profile

NX Pharmagen is a Louisville-based company founded in 02/2010. See NX Pharmagen's revenue, employees, and funding info on Owler, the world's largest community-based business insights platform. NX Pharmagen's Competitors, Revenue, Number of Employees, Funding and Acquisitions.